Competitive pressure is hitting Bayer’s Nutritionals business, with US multivitamins especially tough, the company told HBW ...

The EMA could extend its product development coordinator model to medicines outside PRIME after completing a two-year pilot ...

Drug developers could get a faster way to put focused scientific questions to the European Medicines Agency, as the regulator ...

Ultragenyx will cut about a fifth of its staff and drop its Wilson disease gene therapy to reach profitability in 2027 as it ...

Novo has upgraded its full-year forecast thanks to the huge success of the Wegovy pill, but analysts want to see more action ...

Abbott reported at TCT 2026 that its investigational SonicForce coronary intravascular lithotripsy (IVL) system met its ...

Abbott reported positive one-year results from the VERITAS study of its Amulet 360 left atrial appendage (LAA) closure device ...

Comments on the US FDA's GenAI medical device discussion paper reflect a divide between industry calls for regulatory ...

Oncology Center of Excellence official suggests that patient-reported outcomes may need to be collected more frequently early ...

South Korea issues revised guidance on data requirements for the regulatory evaluation of biosimilar products designed to ...

CEO Bill Anderson tells Scrip that the firm’s speed and cost structure for drug development matches ‘any company in the world ...

The UK’s Trading Standards office found that four in 10 counterfeit cosmetics products tested positive for potentially ...